Tracy Beth Høeg, the head of CDER, is set to depart FDA as part of a broad leadership shake-up that’s rolling through the agency’s senior ranks.
Høeg directed the Center for Drug Evaluation and Research, which oversees new drug and biologics approvals for the U.S. market. Her departure doesn’t stand alone: multiple other top FDA positions are turning over at the same time, suggesting a coordinated restructuring rather than a standalone exit.
The leadership change raises immediate questions for the agency’s drug review operations. CDER sets the review priorities that sponsors plan around. When the director’s seat turns over abruptly, companies mid-review face real uncertainty about who’s making the calls on contested submissions and whether institutional priorities will shift.
Pharmaceutical companies with active applications at the agency can’t sit still while the seat is empty. The practical question is who runs CDER in the interim and what that means for timelines.
No replacement has been announced.
— Sarah Chen